620 related articles for article (PubMed ID: 29733389)
21. Glioblastoma vs temozolomide: can the red queen race be won?
Arora A; Somasundaram K
Cancer Biol Ther; 2019; 20(8):1083-1090. PubMed ID: 31068075
[TBL] [Abstract][Full Text] [Related]
22. Momelotinib sensitizes glioblastoma cells to temozolomide by enhancement of autophagy via JAK2/STAT3 inhibition.
Liu T; Li A; Xu Y; Xin Y
Oncol Rep; 2019 Mar; 41(3):1883-1892. PubMed ID: 30664175
[TBL] [Abstract][Full Text] [Related]
23. EGFR amplified and overexpressing glioblastomas and association with better response to adjuvant metronomic temozolomide.
Cominelli M; Grisanti S; Mazzoleni S; Branca C; Buttolo L; Furlan D; Liserre B; Bonetti MF; Medicina D; Pellegrini V; Buglione M; Liserre R; Pellegatta S; Finocchiaro G; Dalerba P; Facchetti F; Pizzi M; Galli R; Poliani PL
J Natl Cancer Inst; 2015 May; 107(5):. PubMed ID: 25739547
[TBL] [Abstract][Full Text] [Related]
24. Cellular-based immunotherapies for patients with glioblastoma multiforme.
Xu X; Stockhammer F; Schmitt M
Clin Dev Immunol; 2012; 2012():764213. PubMed ID: 22474481
[TBL] [Abstract][Full Text] [Related]
25. Trans sodium crocetinate with temozolomide and radiation therapy for glioblastoma multiforme.
Gainer JL; Sheehan JP; Larner JM; Jones DR
J Neurosurg; 2017 Feb; 126(2):460-466. PubMed ID: 27177177
[TBL] [Abstract][Full Text] [Related]
26. Temozolomide nano enabled medicine: promises made by the nanocarriers in glioblastoma therapy.
Yasaswi PS; Shetty K; Yadav KS
J Control Release; 2021 Aug; 336():549-571. PubMed ID: 34229001
[TBL] [Abstract][Full Text] [Related]
27. Immunomodulation for glioblastoma.
Reardon DA; Wen PY; Wucherpfennig KW; Sampson JH
Curr Opin Neurol; 2017 Jun; 30(3):361-369. PubMed ID: 28368867
[TBL] [Abstract][Full Text] [Related]
28. Phospholipase D1 inhibition sensitizes glioblastoma to temozolomide and suppresses its tumorigenicity.
Kang DW; Hwang WC; Noh YN; Park KS; Min DS
J Pathol; 2020 Nov; 252(3):304-316. PubMed ID: 32725633
[TBL] [Abstract][Full Text] [Related]
29. Radiotherapy-drug combinations in the treatment of glioblastoma: a brief review.
McAleavey PG; Walls GM; Chalmers AJ
CNS Oncol; 2022 Jun; 11(2):CNS86. PubMed ID: 35603818
[TBL] [Abstract][Full Text] [Related]
30. Involvement of Intracellular Cholesterol in Temozolomide-Induced Glioblastoma Cell Death.
Yamamoto Y; Sasaki N; Kumagai K; Takeuchi S; Toyooka T; Otani N; Wada K; Narita Y; Ichimura K; Namba H; Mori K; Tomiyama A
Neurol Med Chir (Tokyo); 2018 Jul; 58(7):296-302. PubMed ID: 29899179
[TBL] [Abstract][Full Text] [Related]
31. Treatment of elderly patients with glioblastoma: a systematic evidence-based analysis.
Zarnett OJ; Sahgal A; Gosio J; Perry J; Berger MS; Chang S; Das S
JAMA Neurol; 2015 May; 72(5):589-96. PubMed ID: 25822375
[TBL] [Abstract][Full Text] [Related]
32. Pharmacological strategies for improving the prognosis of glioblastoma.
Raj D; Agrawal P; Gaitsch H; Wicks E; Tyler B
Expert Opin Pharmacother; 2021 Oct; 22(15):2019-2031. PubMed ID: 34605345
[No Abstract] [Full Text] [Related]
33. Temozolomide treatment outcomes and immunotherapy efficacy in brain tumor.
Hotchkiss KM; Sampson JH
J Neurooncol; 2021 Jan; 151(1):55-62. PubMed ID: 32813186
[TBL] [Abstract][Full Text] [Related]
34. Hypofractionated accelerated radiotherapy (HART) with concurrent and adjuvant temozolomide in newly diagnosed glioblastoma: a phase II randomized trial (HART-GBM trial).
Mallick S; Kunhiparambath H; Gupta S; Benson R; Sharma S; Laviraj MA; Upadhyay AD; Julka PK; Sharma D; Rath GK
J Neurooncol; 2018 Oct; 140(1):75-82. PubMed ID: 29936695
[TBL] [Abstract][Full Text] [Related]
35. Association of patterns of care, prognostic factors, and use of radiotherapy-temozolomide therapy with survival in patients with newly diagnosed glioblastoma: a French national population-based study.
Fabbro-Peray P; Zouaoui S; Darlix A; Fabbro M; Pallud J; Rigau V; Mathieu-Daude H; Bessaoud F; Bauchet F; Riondel A; Sorbets E; Charissoux M; Amelot A; Mandonnet E; Figarella-Branger D; Duffau H; Tretarre B; Taillandier L; Bauchet L
J Neurooncol; 2019 Mar; 142(1):91-101. PubMed ID: 30523606
[TBL] [Abstract][Full Text] [Related]
36. Cost-effectiveness of the long-term use of temozolomide for treating newly diagnosed glioblastoma in Germany.
Waschke A; Arefian H; Walter J; Hartmann M; Maschmann J; Kalff R
J Neurooncol; 2018 Jun; 138(2):359-367. PubMed ID: 29468446
[TBL] [Abstract][Full Text] [Related]
37. Pathological changes after autologous formalin-fixed tumor vaccine therapy combined with temozolomide for glioblastoma - three case reports - .
Sakamoto N; Ishikawa E; Yamamoto T; Satomi K; Nakai K; Sato M; Enomoto T; Morishita Y; Takano S; Ohno T; Tsuboi K; Matsumura A
Neurol Med Chir (Tokyo); 2011; 51(4):319-25. PubMed ID: 21515959
[TBL] [Abstract][Full Text] [Related]
38. Is the absolute value of O(6)-methylguanine-DNA methyltransferase gene messenger RNA a prognostic factor, and does it predict the results of treatment of glioblastoma with temozolomide?
Tanaka S; Akimoto J; Narita Y; Oka H; Tashiro T
J Neurosurg; 2014 Oct; 121(4):818-26. PubMed ID: 25105699
[TBL] [Abstract][Full Text] [Related]
39. Emerging immunotherapies for glioblastoma.
Desai R; Suryadevara CM; Batich KA; Farber SH; Sanchez-Perez L; Sampson JH
Expert Opin Emerg Drugs; 2016 Jun; 21(2):133-45. PubMed ID: 27223671
[TBL] [Abstract][Full Text] [Related]
40. New trends in the medical management of glioblastoma multiforme: the role of temozolomide chemotherapy.
Dehdashti AR; Hegi ME; Regli L; Pica A; Stupp R
Neurosurg Focus; 2006 Apr; 20(4):E6. PubMed ID: 16709037
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
